Edition:
United States

Search Results  for 'IPO-AST.N'

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Asterias Biotherapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Asterias Biotherapeutics Inc (AST-A)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

25 Sep 2016 Thomson Reuters Stock Report 12 $25.00

ValuEngine Rating and Forecast Report for AST

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

25 Sep 2016 ValuEngine, Inc. 11 $25.00

ASTERIAS BIOTHERAPEUTICS INC (AST=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

24 Sep 2016 Pechala's Reports 2 $25.00

Value Graph: ASTERIAS BIOTHER -- AST

23 Sep 2016 Ford Investor Services, Inc. 1 $12.00

Company Snapshot - Asterias Biotherapeutics Inc

Two Directors at Asterias Biotherapeutics Inc sold 34,096 shares at between 3.517USD and 3.519USD. The significance rating of...

12 Sep 2016 Directors Deals Ltd. 1 $12.00

Wright Investors Service Comprehensive Report for Asterias Biotherapeutics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

30 Aug 2016 Wright Reports 60 $75.00

AST.A - Event Transcript of Asterias Biotherapeutics Inc conference call, Aug. 15, 2016 / 4:30PM ET

Edited Event Transcript of AST.A conference call, Aug. 15, 2016 / 4:30PM ET Boston, Aug 25, 2016 (Thomson StreetEvents)...

15 Aug 2016 Thomson Reuters StreetEvents 16 $75.00

Interview with the CEO: Asterias Biotherapeutics, Inc. (NYSEMKT:AST)

12 Aug 2016 Wall Street Transcript ,The 5 $50.00

Thomson Reuters Stock Report - Asterias Biotherapeutics Inc (AST-A)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 12 $25.00